Description

Ipamorelin 10mg – Synthetic Research Peptide

Ipamorelin 10mg is a synthetic peptide intended for laboratory and scientific research. Also identified by the research code NNC-26-0161, Ipamorelin is a pentapeptide that has been investigated as a selective growth hormone secretagogue. Its scientific profile makes it relevant to research involving peptide pharmacology, receptor activity, and growth hormone signalling.

Ipamorelin was originally described in peer-reviewed research as a potent growth hormone secretagogue with activity at the GHRP-like receptor. Early pharmacological studies investigated its effects in cellular and animal models and reported selective growth hormone release compared with several other growth hormone-releasing peptides.

This 10mg Ipamorelin research peptide is intended for qualified research applications rather than human consumption or self-administration. Researchers should evaluate the compound using appropriate laboratory procedures and applicable institutional requirements.

Product Overview

Ipamorelin is a well-characterised synthetic pentapeptide. PubChem and the FDA’s Global Substance Registration System identify its molecular formula as C38H49N9O5, with a molecular weight of approximately 711.85–711.9 g/mol. Its CAS Registry Number is 170851-70-4.

The compound is also associated with the sequence Aib-His-D-2-Nal-D-Phe-Lys-NH2 and the research designation NNC-26-0161.

For this product, the available information identifies the quantity as 10mg. Specific purity, physical form, and batch-level analytical results have not been provided in the supplied product information.

What Is Ipamorelin 10mg?

Ipamorelin is a synthetic pentapeptide classified as a growth hormone secretagogue. Scientific research has examined its interaction with the growth hormone secretagogue receptor, also known as the ghrelin receptor or GHSR.

The original pharmacological publication described Ipamorelin as a selective growth hormone secretagogue and investigated its activity in vitro and in animal models. The study found that Ipamorelin stimulated growth hormone release through a GHRP-like receptor pathway.

The compound is therefore relevant to laboratory research involving peptide-receptor interactions, endocrine signalling, growth hormone pathways, and pharmacological activity.

These findings should be understood in their research context. Results from cell or animal studies do not establish safety or effectiveness for human use.

Research Background

Ipamorelin was first reported in the scientific literature in 1998. Researchers characterised it as a pentapeptide with growth hormone-releasing activity and investigated its pharmacological selectivity in laboratory and animal models.

The research distinguished Ipamorelin from several earlier growth hormone-releasing peptides by examining its effects on growth hormone and other endocrine markers. The published study reported that Ipamorelin produced growth hormone release without the same observed increases in ACTH and cortisol seen with some comparator compounds in the experimental models.

More recent regulatory information requires additional caution. FDA has identified potential concerns relating to the characterisation, aggregation, peptide-related impurities, and immunogenicity of compounded Ipamorelin acetate. FDA has also stated that available safety information is insufficient for certain routes of administration.

Consequently, research findings should not be converted into therapeutic claims or assumptions about human safety.

Research Applications

Ipamorelin may be relevant to qualified laboratory research involving:

• Growth hormone secretagogue activity
• Peptide-receptor interactions
• GHSR-related signalling
• Endocrine and cellular research
• Peptide structure and characterisation
• Pharmacological research
• Analytical peptide research

These applications describe areas of scientific investigation rather than approved medical uses.

This product page does not provide human dosing, administration instructions, treatment protocols, cycles, or recommendations for achieving physiological effects.

Product Specifications

The chemical identifiers and molecular information above are supported by PubChem and the FDA Global Substance Registration System.

Quality & Documentation

For research peptides, analytical documentation is an important part of responsible sourcing. Researchers should review available Certificate of Analysis (COA) information, batch identification, purity testing, analytical methods, and other technical documentation where supplied by the vendor.

The supplied product information does not confirm that a COA or specific batch-testing documentation is available for this product. Therefore, no unverified certification or purity percentage is stated here.

Purity: Specification not provided — contact us for details.

Ordering & Shipping

Before ordering Ipamorelin 10mg, researchers should confirm product availability, applicable research-use requirements, and the supplier’s current shipping policy.

Shipping destinations, delivery times, customs arrangements, warehouse locations, and guarantees have not been provided in the supplied information. These details should therefore be confirmed directly with the supplier rather than assumed.

For international research orders, customers should independently verify applicable import, export, customs, and research-compound requirements before placing an order.

---

8. FAQs

What is Ipamorelin 10mg?

Ipamorelin 10mg is a 10mg formulation of the synthetic peptide Ipamorelin. It is primarily described as a research compound and has been investigated as a selective growth hormone secretagogue.

What is Ipamorelin also known as?

Ipamorelin is also identified by the research designation NNC-26-0161. Its CAS Registry Number is 170851-70-4.

What is the CAS number for Ipamorelin?

The CAS number associated with Ipamorelin is 170851-70-4.

What is Ipamorelin researched for?

Research has investigated Ipamorelin as a growth hormone secretagogue, including its interaction with GHRP-like/GHS receptors and its effects in cellular and animal models.

What is the molecular formula of Ipamorelin?

The molecular formula listed by PubChem and FDA’s substance registration database is C38H49N9O5.

What is the product size?

The supplied product specification identifies the product size as 10mg.

Is Ipamorelin approved for human use?

The product should not be represented as an FDA-approved medicine. FDA has identified safety and characterisation concerns relating to compounded Ipamorelin acetate and states that available information is insufficient for certain routes of administration.

Is Ipamorelin intended for human consumption?

This product page positions Ipamorelin 10mg for qualified research use, not human consumption or self-administration.

---

9. Research-Use Disclaimer

Research Use Only: Ipamorelin 10mg is presented for qualified laboratory and scientific research where legally permitted. It is not presented as a dietary supplement, approved medicine, or product for human consumption.

Researchers and institutions are responsible for complying with applicable laws, regulations, institutional requirements, laboratory safety procedures, and product-specific restrictions.